“A new JACC study led by Gregory Marcus found that regular cannabis users had significantly fewer premature heartbeats on days they smoked or vaped cannabis.”
The UCSF MARY-JANE trial led by Gregory Marcus is real. It uses a randomized, case-crossover design in which participants are instructed to consume or avoid inhaled cannabis while wearing continuous ECG monitors. The post’s 52.5 million figure for U.S. cannabis use in 2021 is also supported.
The post presents results and publication status that are not supported by the trial record. The official registry lists no posted results and estimates primary and overall completion in November 2026; therefore, the stated finding cannot currently be attributed to a completed, published JACC study.
This is not merely missing nuance: the central health finding depends entirely on results that are not yet publicly reported. A reasonable viewer would otherwise believe cannabis was shown to reduce abnormal heartbeats.
Why Clear says this
ClinicalTrials.gov identifies this as the relevant Marcus-led study, with 100 planned participants and outcomes including premature atrial and ventricular contractions. Its status is active, not recruiting; no results are posted; and completion is estimated for November 2026. Independent evidence also remains mixed on cannabis and rhythm outcomes, rather than establishing a protective effect.
Evidence
- ClinicalTrials.gov lists the Marcus-led MARY-JANE trial as active, not recruiting, with no results posted and estimated primary completion in November 2026.
- The registry confirms the trial is designed to compare heart-rhythm measurements on instructed cannabis-use versus abstinence days, but does not report an outcome showing fewer premature beats.
- CDC reports that 52.5 million people used cannabis at least once in 2021.
- An observational MESA analysis found current cannabis use was associated with numerically more, not fewer, arrhythmia measures; several estimates were imprecise, so it does not prove cannabis causes arrhythmias.